San Francisco, California (PRWEB) May 21, 2014
CollabRx, Inc. (NASDAQ: CLRX), a data analytics company and leading provider of expert systems that inform therapeutic decision-making in oncology, today announced the publication of an abstract in the 2014 ASCO Annual Meeting Proceedings. Information about the abstract is as follows:
Title: Genetic alterations in esophageal cancers: Detection by next-generation sequencing and potential for therapeutic targets
Authors: Victoria Meucci Villaflor, Deric Wheeler, Mari Iida, Smruti Vidwans, Michelle Turski, Toni M Brand, Brian Won, Mark K. Ferguson, Marco G. Patti, Mitchell Posner, Irving Waxman, Gavin Gordon, Everett E. Vokes, Ravi Salgia
Category: Tumor Biology
Sub-category: Genomic and Epigenomic Biomarkers
The abstract summarizes the results of a clinical study conducted by physicians and clinical researchers at CollabRx, the University of Chicago, and the University of Wisconsin. The goal of the study was to pair tumor genetic alterations derived from an established next generation sequencing (NGS) platform with actionable information that can be used to inform individual patient treatment planning. In the study, NGS data was obtained from standard Foundation Medicine genomic profiling reports, i.e., the FoundationOne® test for solid tumors. The CollabRx Genetic Variant Annotation (GVA) Service™ was then used to independently interpret FoundationOne test results on an individual patient basis and provide information on associated drugs and clinical trials.
This analysis highlighted several practical advantages of the GVA Service compared to the interpretation provided with the original FoundationOne® test reports. The CollabRx GVA Service identified an expanded list of drugs associated with specific genetic alterations and provided the relevant justification, categorized by evidence level. Also, the GVA Service provided lists of curated clinical trials matched to each patient’s tumor genetic profile. These lists include trials that are open to enrollment, are recruiting for the patients’ tumor types, and when relevant, include those trials where the observed genetic alteration is described in the trial inclusion criteria.
“We are pleased to collaborate with leading academic centers to advance the broad use of tumor genetic profiles to inform individual patient treatment planning,” said Thomas Mika, chairman, president & CEO of CollabRx. “The results of our study attest to the ability for any laboratory or physician to access an actionable interpretive report based on tumor NGS testing conducted on any platform.”
CollabRx will be available to discuss the abstract and GVA Service at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3, 2014 in Chicago (CollabRx Exhibitor Booth #4020).
FoundationOne® is a registered trademark of Foundation Medicine, Inc.
CollabRx, Inc. (NASDAQ: CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.
About the CollabRx GVA Service
The GVA Service offered by CollabRx is a widely used, highly scalable, and cloud-based electronic decision support system that provides a turn-key analysis of many types of genetic alterations in cancer. The GVA Service accepts genetic data from any source or platform and pairs it with information contained in a knowledge base that includes the clinical impact of specific genetic profiles. The CollabRx knowledge base is supported by a proprietary technology platform and expert system that leverages a large and growing network of over 75 thought-leaders and clinical practitioners in the United States and Europe who work together with CollabRx to develop new tools for clinical decision-making in oncology. The GVA Service is offered to customers in a Software as a Service (SaaS) business model.
CollabRx Safe Harbor Statement
This press release includes forward-looking statements about CollabRx’s anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and CollabRx’s plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx with the Securities and Exchange Commission. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.